Design and Rationale for a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Trial of Oral Arimoclomol in Inclusion Body Myositis
AuthID
P-017-N8S
P-017-N8S
© 2025 CRACS & Inesc TEC - All Rights Reserved Privacy Policy | Terms of Service